A small antibiotic called plectasin uses an innovative mechanism to kill bacteria. By assembling into large structures, plectasin latches onto its target on the bacterial cell surface comparable to how both sides of Velcro form a bond.
Tharimmune’s public offering; Culmination Bio raises $10M; Pepper Bio’s seed round led by NFX
Tharimmune closes $11M in public offering: The company, which is developing therapies that aim to treat rare, inflammatory, and oncologic conditions, announced Thursday that it
December 2, 2023